Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28484414 | 0.94 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL6595211 | 0.94 | AGTR1 (0.52) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL991977 | 0.92 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1275437 | 0.92 | AGTR1 (0.55) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Potassium Ion SCHEMBL16872384 | 0.90 | AGTR1 (0.60) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL992501 | 0.89 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL94332 | 0.89 | AGTR1 (0.74) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL9259068 | 0.89 | AGTR1 (0.52) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL16872178 | 0.89 | AGTR1 (0.62) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1966071 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | claimed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| CN-118255753-A | Synthesis method of olmesartan medoxomil intermediate | 黄冈鲁班药业股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-2891650-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-9624181-B2 | Method for producing biaryl compound | API CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2891650-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API Corporation (JP) | 2015-07-08 | — | — | EP | disclosed |
| WO-2011007368-A3 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011036674-A1 | A NEW PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | INOGENT LABORATORIES PRIVATE LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011014611-A2 | PREPARATION OF OLMESARTAN MEDOXOMIL | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20090069397-A1 | DEUTERIUM-ENRICHED OLMESARTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069397-A1 | DEUTERIUM-ENRICHED OLMESARTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1916246-A3 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | disclosed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | MLX, BMX, BRIX1 | AGTR1 1993/4885AGTR2 954/4885ABCC3 1950/4885 |
| US-20090069397-A1 | DEUTERIUM-ENRICHED OLMESARTAN | REN, NR3C2, AVPR2 | AGTR1 4/4885AGTR2 6/4885ABCC3 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.